Caring for patients with MM is very challenging. The availability and activity of modern chemotherapy regimens as well as newer classes of drugs with novel mechanisms of action in addition to aggressive transplant regimens has collectively changed the course of MM to that of a chronic disease for a sizeable number of patients. Hence, patients will potentially be receiving several courses of therapy and proper supportive care can enhance QOL and delay or prevent serious complications. Finally, oncology practitioners need to realize that progressive renal insufficiency, anemia, or infection may all herald disease relapse. Therefore, it is reasonable to reassess all parameters of renal and hepatic function in addition to requantification of marrow plasma cell burden and paraproteins in a previously stable patient with new or progressive symptoms.
Was this article helpful?